Find investors
← Back to all investors
RF
ResearchedAngel Investors

Richard Falconer

Chief Financial Officer

Angel InvestorsSeed Round
Pitch Richard

Get their honest, personalized take on your startup.

Sign in to pitch Richard →

At a glance

Full Name
Richard "Rick" Falconer
Title
Senior Managing Director
Firm
Coremix Capital, LLC
Firm Type
Family office / private equity investor
Investment Stage
Growth financing, recapitalizations, buyouts, acquisition financings, corporate divestitures, sponsored and unsponsored transactions
Check Size
$1 million to $15 million initial investments
Target Company Profile
U.S. middle-market companies that need subordinated debt and/or equity capital, operational guidance, and growth capital
Sector Focus
Consumer products, food, life science, manufacturing, real estate, healthcare services, education, machinery, medical products, software, consumer-focused technology, gaming, and mobile/software
Geographic Focus
United States
Location
Vancouver, Washington

Background

Richard "Rick" Falconer is a Senior Managing Director at Coremix Capital, LLC, a Vancouver, Washington-based family office and investment firm founded in 2013. Coremix describes itself as the investment and management arm of a family office, with specialties including acquisition and growth financings, accounts receivable financing, real estate acquisitions, equipment leasing/purchases, and brand building.

Before Coremix, Falconer was Chief Financial Officer of Avid Health, Inc., the Vancouver-based maker of Vitafusion and L'il Critters gummy vitamins. In Church & Dwight's 2012 stock purchase agreement for Avid Health, Richard Falconer signed on behalf of Avid Health as Chief Financial Officer. Church & Dwight completed the Avid Health acquisition on October 1, 2012 for approximately $650 million; its 2012 annual report recorded the purchase price at $652.3 million.

Falconer's earlier career included finance roles at Interlogix Corp., General Electric, and Arthur Andersen LLP. MarketScreener lists him as previously VP Finance at Interlogix, Audit Manager at Arthur Andersen, and a principal at General Electric. His education is listed as Oregon State University.

Investment Thesis & Focus

  • Coremix provides flexible capital across the debt-equity spectrum, combining financing with business insight and operational guidance.
  • The firm says: "Initial investments range from $1 to $15 million."
  • Coremix invests in companies "at all stages of their development," but its disclosed deal history is concentrated in growth capital and middle-market financing rather than seed angel investing.
  • Transaction types include recapitalizations, management-led buyouts, growth financing, corporate divestitures, acquisition financings, and sponsored or unsponsored transactions.
  • Coremix emphasizes founder/operator support: it says it understands entrepreneurs, has "a passion for growing companies," and focuses on translating vision into execution, managing risk, and maximizing profitability.
  • Falconer's MobileRQ quote suggests interest in category growth and customer engagement: he said MobileRQ could help customers "engage with consumers in significant ways whenever and wherever they are."

Notable Investments

  • MobileRQ - Portland contextual mobile marketing platform for travel, hospitality, loyalty, and retail brands; Coremix participated in a June 2014 round alongside Verizon Ventures, Rogue Ventures, and TiE Oregon.
  • Consensus Orthopedics - El Dorado Hills medical products company designing and distributing reconstructive hip and knee implants; Mergr lists Coremix as a seller when Shalby acquired the company on May 17, 2021 for $11 million.
  • BMM Testlabs / BMM International - Las Vegas gaming testing, certification, and regulatory compliance business; Mergr lists Coremix as an investor in an August 1, 2013 growth capital transaction.
  • Avid Health - Not a Coremix investment, but a central operating background for Falconer and the Coremix founding group; Church & Dwight acquired Avid Health in 2012 for approximately $650 million.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.